OmniAb, Inc. — fact timeline

OmniAb, Inc. shareholders approved Ratification of Ernst & Young LLP as independent auditor at the 2026-06-17 meeting.

“The appointment was ratified by the votes indicated: For Against Abstain Broker Non-Votes 102,163,551 112,653 135,380 0”

OmniAb, Inc. shareholders approved Election of two Class I directors at the 2026-06-17 meeting.

“The following two Class I directors were elected by the votes indicated: For Withheld Broker Non-Votes Jennifer Cochran, Ph.D. 57,948,696 25,997,984 18,464,904 Matthew W. Foehr 82,231,849 1,714,831 18,464,904”

OmniAb, Inc. reported the three months ended March 31, 2026 results: revenue $14.4 million. Guidance raised.

“as demonstrated by the launch of OmniUltra TM and our xPloration ® partner access program. ” First Quarter 2026 Financial Results Revenue for the first quarter of 2026 was $14.4 million , compared with $4.2 million for the same period in 2025 , with the increase primarily related to milestone revenue . Research and development expense was $9.6 million for the”

OmniAb, Inc. updated its fiscal year 2026 guidance (initiated).

“OmniAb expects 2026 revenue to be in the range of $25 million to $30 million, and costs and operating expenses to be in the range of $80 million to $85 million.”

OmniAb, Inc. reported the year ended December 31, 2025 results: revenue $18.7 million, net income $64.8 million, EPS $0.57 per share.

“Revenue for 2025 was $18.7 million, compared with $26.4 million for 2024. The decline was primarily due to a decrease in license revenue of $2.5 million and milestone revenue of $1.6 million. Service revenue declined as a result of the completion or discontinuation of certain legacy small molecule ion channel programs. These decreases were offset by the addition of $0.8 million in xPloration revenue reflecting the sale of an instrument and related consumables. Cost of xPloration revenue was $0.3 million for 2025 and consisted of direct costs associated with the sale of the xPloration instrument and associated consumables. Research and development expense was $47.8 million for 2025 , compared with $55.1 million for 2024, primarily due to lower personnel expenses related to reduced headcount and share-based compensation expense, lower external expenses associated with legacy small molecule ion channel programs and a decline in contract research costs, partially offset by a $3.9 million i”

OmniAb, Inc. reported the fourth quarter of 2025 results: revenue $8.4 million, net income $14.2 million, EPS $0.11 per share.

“Revenue for the fourth quarter of 2025 was $8.4 million, compared with $10.8 million for the same period in 2024, with the decrease primarily related to a decline in license revenue and service revenue, partially offset by an increase in milestone and royalty revenue and the addition of xPloration revenue . Research and development expense was $13.9 million for the fourth quarter of 2025, compared with $13.3 million for the same period in 2024, with the increase due to a $3.9 million impairment charge primarily related to certain small molecule ion channel property and equipment, partially offset by lower personnel expenses related to reduced headcount and share-based compensation expense, and lower external expenses associated with legacy small molecule ion channel programs. General and administrative expense was $6.8 million for the fourth quarter of 2025, compared with $7.4 million for the same period in 2024, with the decrease primarily due to lower share-based compensation expense”

OmniAb, Inc.: Amended and restated bylaws to address universal proxy rules and modernize stockholder meeting procedures (effective 2026-01-30).

“On January 30, 2026, the Board of Directors (the “Board”) of OmniAb, Inc. (the “Company”) approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), which became effective the same day.”

Philip J. Gotwals was appointed as Director at OmniAb, Inc..

“the Board appointed Steven C. Crouse and Philip J. Gotwals, Ph.D. to the Board”

Steven C. Crouse was appointed as Director at OmniAb, Inc..

“the Board appointed Steven C. Crouse and Philip J. Gotwals, Ph.D. to the Board”

Joshua Tamaroff resigned as Director at OmniAb, Inc..

“On June 27, 2024, Joshua Tamaroff resigned from the Board of Directors (the “Board”) and Audit Committee of the Board (the “Audit Committee”) of OmniAb, Inc. (the “Company”), effective June 28, 2024, due to his pending departure from Avista Capital Partners.”

OmniAb, Inc. reported the first quarter of 2024 results: revenue $3.8 million, net income $19.0 million net loss, EPS $0.19 per share loss.

“to continued progress by our partners and expansion of our technology as the year progresses.” First Quarter 2024 Financial Results Revenue for the first quarter of 2024 was $3.8 million, compared with $16.9 million for the same period in 2023, with the decrease primarily due to the recognition in the 2023 period of a $10 million milestone related to the first”

OmniAb, Inc. reported the three months ended March 31, 2024 results: revenue $3.8 million, net income $19.0 million net loss, EPS $0.19 per share loss.

“to continued progress by our partners and expansion of our technology as the year progresses.” First Quarter 2024 Financial Results Revenue for the first quarter of 2024 was $3.8 million, compared with $16.9 million for the same period in 2023, with the decrease primarily due to the recognition in the 2023 period of a $10 million milestone related to the first”

OmniAb, Inc. reported 12 months ended December 31, 2023 results: revenue $34.2 million, net income $50.6 million, EPS $0.51 per share.

“or $0.14 per diluted share, compared with net income of $6.8 million, or $0.07 per share, for the same period in 2022. Full Year 2023 Financial Results Revenue for 2023 was $34.2 million, compared with $59.1 million for 2022, with the decrease primarily due to the recognition of TECVAYLI ® milestones of $10.0 million in 2023 compared with $25.0 million in 2022.”

OmniAb, Inc. reported three months ended December 31, 2023 results: revenue $4.8 million, net income $14.1 million, EPS $0.14 per diluted share.

“as we are now staffed and resourced to efficiently leverage the future growth of the business.” Fourth Quarter 2023 Financial Results Revenue for the fourth quarter of 2023 was $4.8 million, compared with $35.3 million for the same period in 2022, with the decrease primarily due to the recognition of a $25.0 million milestone payment in the prior-year period related”

OmniAb, Inc. reported three and nine months ended September 30, 2023 results: revenue $5.5 million, net income $15.7 million, or $0.16 per share.

“Virtual Event later today, which will include an overview of our new Omni dAb TM technology.” Third Quarter 2023 Financial Results Revenue for the third quarter of 2023 was $5.5 million, compared with $6.9 million for the same period in 2022, with the decrease primarily driven by lower service revenue as a result of the completion of discovery work on certain”

Steven Love was appointed as Director at OmniAb, Inc..

“On November 1, 2023, the board of directors (the “Board”) of OmniAb, Inc. (the “Company”) appointed Steven Love as a member of the Board.”

OmniAb, Inc. reported the three and six months ended June 30, 2023 results: revenue $6.9 million, net income $14.7 million, or $0.15 per share, EPS $0.15 per share.

“related to our current partners as well as to securing additional partnerships,” he added. Second Quarter 2023 Financial Results Revenue for the second quarter of 2023 was $6.9 million, compared with $7.2 million for the same period in 2022. Milestone revenue was higher due to progress with the batoclimab program. Service revenue was lower primarily related to”

OmniAb, Inc. shareholders approved The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-23 meeting.

“Proposal 2. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The appointment was ratified by the votes indicated: For Against Abstain Broker Non-Votes 87,761,330 224,020 25,982 0”

OmniAb, Inc. shareholders approved The election of two directors to serve as Class I directors for a three-year term to expire at the 2026 Annual Meeting of Stockholders. at the 2023-06-23 meeting.

“Proposal 1. The election of two directors to serve as Class I directors for a three-year term to expire at the 2026 Annual Meeting of Stockholders. The following two Class I directors were elected by the votes indicated: For Against Withheld Broker Non-Votes Matthew W. Foehr 73,222,386 665,930 419,424 13,703,592 Jennifer Cochran, Ph.D. 69,340,824 4,553,603 413,313 13,703,592”

OmniAb, Inc. reported the three months ended March 31, 2023 results: revenue $16.9 million, net income $6.1 million, EPS $0.06 per share.

“Revenue for the first quarter of 2023 was $16.9 million, compared with $9.6 million for the same period in 2022, with the increase primarily due to the recognition of a $10.0 million milestone payment related to the first commercial sale of TECVAYLI® (teclistamab) in the European Union. Research and development expense was $13.8 million for the first quarter of 2023, compared with $10.8 million for the same period in 2022, with the increase primarily due to investments in facilities, headcount and technology innovation. General and administrative expense was $8.2 million for the first quarter of 2023, compared with $4.1 million for the same period in 2022, with the increase primarily due to higher headcount and other expenses related to being an independent publicly traded company. Net loss for the first quarter of 2023 was $6.1 million, or $0.06 per share, compared with a net loss of $6.3 million, or $0.08 per share, for the same period in 2022.”

OmniAb, Inc. reported financial results for three months and full year ended December 31, 2022.

“On March 30, 2023, OmniAb Incorporated (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2022.”

OmniAb, Inc. reported the nine months ended September 30, 2022 results: revenue $23.7 million, net income $29.2 million.

“Revenue for the nine months ended September 30, 2022 was $23.7 million, compared with $19.5 million for the same period in 2021, with the increase driven by higher milestone revenue, higher royalty revenue due to the launch of zimberelimab and sugemalimab in China and additional collaboration revenue. Research and development expense was $35.4 million for the nine months ended September 30, 2022, compared with $28.2 million for the same period of 2021, with the increase primarily due to continued investment in facilities and headcount. General and administrative expense was $14.7 million for the nine months ended September 30, 2022, compared with $12.6 million for the same period in 2021, with the increase primarily due to the spin-off and business combination, as well as headcount-related expenditures. Net loss for the nine months ended September 30, 2022 was $29.2 million, compared with net loss of $24.0 million for the same period in 2021.”

OmniAb, Inc. reported the three months ended September 30, 2022 results: revenue $6.9 million, net income $12.6 million.

“Revenue for the third quarter of 2022 was $6.9 million, compared with $6.3 million for the same period in 2021, with the increase primarily driven by higher royalty revenue due to the launch of zimberelimab and sugemalimab in China. Research and development expense was $13.2 million for the third quarter of 2022, compared with $9.9 million for the same period in 2021, with the increase primarily due to continued investment in facilities, headcount and technology innovation initiatives. General and administrative expense was $5.6 million for the third quarter of 2022, compared with $3.7 million for the same period in 2021, with the increase primarily due to headcount-related expenditures in preparation for becoming an independent publicly traded company. Net loss for the third quarter of 2022 was $12.6 million, compared with a net loss of $7.9 million for the same period in 2021.”

OmniAb, Inc.: Company ceased being a shell company due to business combination.

“As a result of the Business Combination, the Company ceased being a shell company.”

OmniAb, Inc. underwent a change of control involving Ligand Pharmaceuticals Incorporated for Each share of Legacy OmniAb common stock converted into 4.90007 shares of OmniAb common stock and 0.75842 earnout shares. (closed 2022-11-01).

“upon the consummation of the Merger, each outstanding share of Legacy OmniAb Common Stock (other than treasury shares) was cancelled in exchange for the right to receive 4.90007 shares of OmniAb Common Stock and 0.75842 shares of OmniAb Common Stock subject to certain price-based earnout triggers (the “Earnout Shares”). In addition, all outstanding Legacy”

OmniAb, Inc. completed an acquisition involving Ligand Pharmaceuticals Incorporated for Each share of Legacy OmniAb common stock converted into 4.90007 shares of OmniAb common stock and 0.75842 earnout shares. (closed 2022-11-01).

“upon the consummation of the Merger, each outstanding share of Legacy OmniAb Common Stock (other than treasury shares) was cancelled in exchange for the right to receive 4.90007 shares of OmniAb Common Stock and 0.75842 shares of OmniAb Common Stock subject to certain price-based earnout triggers (the “Earnout Shares”). In addition, all outstanding Legacy”

OmniAb, Inc.: Adopted new Code of Business Conduct and Ethics (effective 2022-11-01).

“On November 1, 2022, the Board approved and adopted a new Code of Business Conduct and Ethics applicable to all employees, officers and directors of OmniAb.”

OmniAb, Inc.: Adopted new Bylaws effective as of closing of business combination.

“Prior to the Business Combination, the Board approved and adopted the Bylaws of OmniAb (the “Bylaws”), which became effective as of the Effective Time.”

OmniAb, Inc.: Amended Certificate of Incorporation to reflect changes from business combination (effective 2022-10-31).

“The Certificate of Incorporation of the Company (the “Certificate of Incorporation”), which became effective upon filing with the Secretary of State of the State of Delaware on October 31, 2022, includes the amendments proposed by the Charter Proposals.”

OmniAb, Inc. entered into Agreement and Plan of Merger with APAC, Orwell Merger Sub Inc., Ligand, Legacy OmniAb (effective 2022-03-23).

“APAC entered into the Agreement and Plan of Merger (the “Merger Agreement”), dated as of March 23, 2022, by and among APAC, Orwell Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of APAC (“Merger Sub”), Ligand and Legacy OmniAb”

OmniAb, Inc. engaged Ernst & Young LLP as its auditor.

“On November 1, 2022, the Board approved the engagement of EY as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ending December 31, 2022”

OmniAb, Inc. dismissed Marcum LLP as its auditor.

“On November 1, 2022, the Board dismissed Marcum LLP (“Marcum”), APAC’s independent registered public accounting firm prior to the Business Combination, as the Company’s independent registered public accounting firm effective immediately following the filing of the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2022”

Charles Harwood was elected as Director at OmniAb, Inc..

“elected Charles Harwood to serve as a director of the Company and appointed Mr. Harwood to serve as a member of the Audit Committee.”